Tecan Group AG stock analysis
Tecan Group AG (0QLN) Share Price & Analysis
0QLN Stock Chart & Stats
- Day’s Range
- CHF 248.00 - CHF 253.80
- 52-Week Range
- CHF 111.00 - CHF 276.60
- Previous Close
- CHF 251.62
- Volume
- N/A
- Average Volume (3M)
- 13.26K
- Market Cap
- CHF 3.19B
- Enterprise Value
- CHF 2.00B
- Total Cash (Recent Filing)
- CHF 224.63M
- Total Debt (Recent Filing)
- CHF 214.32M
- Price to Earnings (P/E)
- ―
- Beta
- 1.34
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- 3.83
- Last Dividend Ex-Date
- Apr 17, 2026
- Dividend Yield
- 1.21%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Low leverage gives Tecan financial flexibility to fund automation growth, support customer programs, and absorb operating volatility without excessive debt pressure. This strengthens resilience while management executes its transformation and pursues its longer-term sales and margin targets.
Above-Market Operating Traction
Positive local-currency growth, broad segment expansion, and a book-to-bill ratio above one indicate improving demand rather than reliance on a single product or geography. Sustained order momentum can support revenue visibility and strengthen the installed base over coming quarters.
Resilient Cash Generation
Positive operating cash flow through the recent earnings downturn demonstrates that Tecan’s business continues to convert activity into cash despite weaker reported profitability. This supports investment in products, service capabilities, and transformation while reducing dependence on external financing.
Bears Say
Declining Revenue And Profitability
Three consecutive years of revenue decline and a sharp earnings deterioration weaken the company’s current financial foundation. The compressed operating margin leaves less room to absorb cost inflation or execution problems, while the 2025 net loss raises questions about the durability of earnings recovery.
Weaker Cash Conversion And Liquidity
Lower operating cash flow alongside higher receivables and inventory indicates that reported business activity is converting less efficiently into cash. Continued working-capital pressure could constrain funding for growth and transformation, even though the balance sheet currently remains conservatively leveraged.
OEM Shipment Execution Risk
Cavro shipment constraints directly limited Partnering revenue by preventing delivery of existing backlog, showing that execution issues can delay monetization of OEM demand. A gradual recovery is expected, but continued disruption could weigh on segment growth and customer relationships over the next several months.
Tecan Group AG News
0QLN FAQ
What was Tecan Group AG’s price range in the past 12 months?
What is Tecan Group AG’s market cap?
When is Tecan Group AG’s upcoming earnings report date?
How were Tecan Group AG’s earnings last quarter?
Is Tecan Group AG overvalued?
Does Tecan Group AG pay dividends?
What is Tecan Group AG’s EPS estimate?
How many shares outstanding does Tecan Group AG have?
What happened to Tecan Group AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tecan Group AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tecan Group AG
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Monica Manotas
- Employees
- 3,000
- Website
- www.tecan.com
- Address
- Seestrasse 103, Männedorf, ZH, 8708, CH
Tecan Group AG (0QLN) Earnings & Revenues
0QLN Company Deck
0QLN Earnings Call
Earnings Call SentimentPositive
The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.
View all GB:0QLN earnings summaries0QLN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 6 | 7 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 6 | 0 | 6 |













